ST2 has been a research focus in clinical cardiovascular disease since the American College of Cardiology Foundation/Heart Association (ACCF/AHA) formally listed sST2 as a biomarker of myocardial fibrosis in 2013. The gene discussed is IL1RL1; the disease is cardiovascular disorder.